✦ LIBER ✦

Elevated plasma tissue inhibitor of metalloproteinase-1 levels predict decreased survival in castration-resistant prostate cancer patients

✍ Scribed by William K. Oh; Roberto Vargas; Susanna Jacobus; Kim Leitzel; Meredith M. Regan; Peter Hamer; Karen Pierce; Sheryl Brown-Shimer; Walter Carney; Suhail M. Ali; Philip W. Kantoff; Allan Lipton

Publisher: John Wiley and Sons
Year: 2010
Tongue: English
Weight: 220 KB
Volume: 117
Category: Article
ISSN: 0008-543X
DOI: 10.1002/cncr.25394

No coin nor oath required. For personal study only.

✦ Synopsis

Abstract

BACKGROUND.

Tissue inhibitor of metalloproteinase‐1 (TIMP‐1) has paradoxical multifunctional roles in tumorigenesis: inhibition of the catalytic activity of matrix metalloproteinases and apoptosis as well as promotion of angiogenesis and tumor growth. Elevated TIMP‐1 levels have been associated with a poorer prognosis in multiple cancers.

METHODS.

Ethylenediaminetetraacetic acid plasma TIMP‐1 was determined in 362 castration‐resistant prostate cancer (PC) patients using a TIMP‐1 enzyme‐linked immunosorbent assay. All patients with castration‐resistant PC and available plasma were identified from an institutional database. Overall survival was analyzed using the Kaplan‐Meier method and Cox modeling on plasma TIMP‐1 tertiles.

RESULTS.

Patients were evaluated in pilot (n = 60) and primary (n = 302) sets. Median follow‐up from diagnosis was 5.8 and 6.6 years, respectively. Median plasma TIMP‐1 levels were 335 and 183 ng/mL in the pilot and primary sets, respectively. Overall survival was significantly shorter with each higher tertile of TIMP‐1 in both datasets (P<.001). For the primary cohort, hazard ratio of (HR) death and median survival by plasma TIMP‐1 tertile levels were: low, HR 1.0, 43 months; middle, HR 1.7, 27 months; high, HR 2.4, 19 months. In the primary set, significant covariates in the adjusted Cox regression model were: TIMP‐1 level (mid or high vs low tertile), prostate‐specific antigen (>20 vs ≤20 ng/mL), alkaline phosphatase (>102 vs ≤102 U/L), Eastern Cooperative Oncology Group performance status (1 + vs 0), and Gleason score (7 or 8 vs ≤6).

CONCLUSIONS.

📜 SIMILAR VOLUMES

Elevated plasma tissue inhibitor of meta

Elevated plasma tissue inhibitor of metalloproteinase-1 level predicts decreased response and survival in metastatic breast cancer

✍ Allan Lipton; Suhail M. Ali; Kim Leitzel; Laurence Demers; Dean B. Evans; Peter 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 151 KB

## Abstract ## BACKGROUND. Tissue inhibitors of metalloproteinase (TIMPs) have at least 2 different functions. They inhibit the catalytic activity of matrix metalloproteinases, and they act as growth factors. ## METHODS. Pretreatment ethylenediamine tetracetic acid plasma TIMP‐1 was assayed from

High levels of tissue inhibitor of metal

High levels of tissue inhibitor of metalloproteinase-1 predict poor outcome in patients with breast cancer

✍ Kevin McCarthy; Teresa Maguire; Gerald McGreal; Enda McDermott; Niall O'Higgins; 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 French ⚖ 67 KB 👁 2 views

Studies from model systems suggest that matrix metalloproteinases (MMPs) are causally involved in tumor progression while tissue inhibitors of MMPs (TIMPs) prevent this progression. Here, we show that concentrations of TIMP-1 are significantly higher in breast carcinomas than in fibroadenomas. In pr

Matrix metalloproteinases 1 and 3, tissu

Matrix metalloproteinases 1 and 3, tissue inhibitor of metalloproteinase-1 and the complex of metalloproteinase-1/tissue inhibitor in plasma of patients with prostate cancer

✍ Klaus Jung; Lars Nowak; Michael Lein; Friedrich Priem; Dietmar Schnorr; Stefan A 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 French ⚖ 74 KB 👁 1 views

We analyzed blood plasma concentrations of matrix metalloproteinase-1 and -3 (MMP-1; MMP-3), the tissue inhibitor of metalloproteinase-1 (TIMP-1) and the complex MMP-1/ TIMP-1, and looked for any correlation with prostate cancer stage. These components were measured by ELISA tests specific for these